VUMERITY Drug Patent Profile

Which patents cover Vumerity, and when can generic versions of Vumerity launch?

Vumerity is a drug marketed by Biogen Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in thirty-one countries.

The generic ingredient in VUMERITY is diroximel fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the diroximel fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vumerity

A generic version of VUMERITY was approved as diroximel fumarate by ZYDUS on November 12^th, 2025.

Summary for VUMERITY

International Patents:	60
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	4
Patent Applications:	349
Drug Prices:	Drug price information for VUMERITY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VUMERITY
What excipients (inactive ingredients) are in VUMERITY?	VUMERITY excipients list
DailyMed Link:	VUMERITY at DailyMed

See drug prices for VUMERITY

Recent Clinical Trials for VUMERITY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Nebraska	EARLY_PHASE1
Biogen	Phase 1
Biogen	Phase 3

See all VUMERITY clinical trials

Paragraph IV (Patent) Challenges for VUMERITY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VUMERITY	Delayed-release Capsules	diroximel fumarate	231 mg	211855	1	2020-12-23

US Patents and Regulatory Information for VUMERITY

VUMERITY is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen Inc	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes	9,090,558
Biogen Inc	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes	10,080,733		Y	Y
Biogen Inc	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes	8,669,281		Y	Y

EU/EMA Drug Approvals for VUMERITY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Biogen Netherlands B.V.	Vumerity	diroximel fumarate	EMEA/H/C/005437Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established).	Authorised	no	no	no	2021-11-15

International Patents for VUMERITY

When does loss-of-exclusivity occur for VUMERITY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VUMERITY around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	2970101
Lithuania	2970101
Israel	241440
Finland	2970101
Canada	2906580
New Zealand	723459	Prodrugs of fumarates and their use in treating various diseases
Croatia	P20181169

Supplementary Protection Certificates for VUMERITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2970101	C202230010	Spain		PRODUCT NAME: FUMARATO DE DIROXIMEL; NATIONAL AUTHORISATION NUMBER: EU/1/21/1585; DATE OF AUTHORISATION: 20211115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 68066; DATE OF FIRST AUTHORISATION IN EEA: 20210920
2970101	301165	Netherlands		PRODUCT NAME: DIROXIMELFUMARAAT; REGISTRATION NO/DATE: 68066 20210920
2970101	2022/012	Ireland		PRODUCT NAME: DIROXIMEL FUMARATE; REGISTRATION NO/DATE: EU/1/21/1585/001 EU/1/21/1585/002 20211115
2970101	22C1011	France		PRODUCT NAME: DIROXIMEL FUMARATE; NAT. REGISTRATION NO/DATE: EU/1/21/1585 20211116; FIRST REGISTRATION: CH - 68066 20210920
2970101	2290010-4	Sweden		PRODUCT NAME: DIROXIMELFUMARAT; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/21/1585, 2021-11-16; PRV HAR FATTAT BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 2290042-7 2290031-0 1590027-7 1590062-4 2190040-2 2290010-4 1990014-1 2190030-3 1590011-1 1490013-8 1490014-6 1490015-3 1890033-2 1990042-2 1990055-4 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS.
2970101	LUC00251	Luxembourg		PRODUCT NAME: DIROXIMEL FUMARATE; AUTHORISATION NUMBER AND DATE: 68066; 20210920
2970101	SPC/GB22/011	United Kingdom		PRODUCT NAME: DIROXIMEL FUMARATE; REGISTERED: CH CH 68066 20210920; UK PLGB 22407/0026-0001 20211108; UK SEE MA ON IPSUM 20211108

Market Dynamics and Financial Trajectory of VUMERITY (Diroximel Fumarate): An In-Depth Analysis

Last updated: January 4, 2026

Executive Summary

VUMERITY (diroximel fumarate) is an oral disease-modifying agent (DMT) approved for relapsing forms of multiple sclerosis (MS). Since its regulatory approval in October 2019 by the FDA, VUMERITY has experienced significant market penetration within the competitive landscape of MS therapeutics. This article explores the macro and micro-market dynamics shaping its trajectory, evaluates financial performance indicators, and anticipates future market trends based on current data and strategic insights.

---

What is VUMERITY, and How Does It Position in the MS Therapeutics Landscape?

VUMERITY (diroximel fumarate):
A prodrug of dimethyl fumarate (DMF), it offers similar efficacy with an improved tolerability profile, notably reduced gastrointestinal (GI) side effects compared to Tecfidera (DMF). Its mechanism involves anti-inflammatory and neuroprotective pathways, primarily acting on the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.

Regulatory and Indication Status:

• Approved by FDA in October 2019 for relapsing MS (RMS)
• Marketed by Biogen Inc., a dominant player in MS therapeutics

Key Differentiators:	Feature	VUMERITY	Tecfidera (DMF)	Competitive Edge
GI Tolerability	Improved	Standard	Yes
Dosing Name	Switch Multivitamin	Oral capsule	Yes
Approval Date	2019	2013	N/A
Market Position	Niche, growing	Market leader	N/A

---

How Do Market Dynamics Shape VUMERITY’s Trajectory?

1. Competitive Landscape of MS Therapeutics

The MS therapeutic market is highly competitive, with key players including Biogen, Roche, Novartis, and Sanofi. The landscape is shaped by:

• Multiple-Sclerosis Drug Class: Injectable, oral, and infusion therapies.
• Market Share Concentration: Biogen dominates with Tecfidera (DMF) commanding approx. 40-45% as of 2022.
• Pipeline and Innovation: Novel oral agents like ozanimod (Roche), siponimod (Novartis), and cladribine influence competition.

Market Share Distribution (2022):	Drug	Market Share	Type	Approval Year
Tecfidera	43%	Oral DMT	2013
VUMERITY	7%	Oral DMT	2019
Mavenclad	4%	Oral Cytotoxic	2017
Others	46%	Varied	N/A

2. Patient Population & Adoption Drivers

Globally, over 2.8 million people suffer from MS, with approximately 70% diagnosed with relapsing forms. The barriers to VUMERITY adoption include:

• Physician preferences favoring well-established drugs
• Patient adherence, especially gastrointestinal tolerability
• Pricing and reimbursement policies, notably in Medicare and private insurers

3. Pricing Strategies and Reimbursement Policies

• VUMERITY’s Pricing:
  List Price ~\$87,600 annually (US). Comparable to Tecfidera but with considerations for formulary access.
• Reimbursement Dynamics:
  Favorable coverage in Medicare Part D and private insurance enhances adoption. Reimbursement is often aligned with Tecfidera, enabling switching and substitution.

4. Regulatory and Epidemiological Factors

• Regulatory Approvals:
  VUMERITY’s approval in multiple territories (EU, Japan, Canada) bolsters sales potential.
• Epidemic Growth:
  Increasing MS prevalence, global diagnostic rates, and aging populations favor market expansion.

5. Patient-centric Factors

• Side-Effect Profile:
  Reduced GI side effects compared to Tecfidera increases patient adherence.
• Treatment Switching:
  Physicians prefer VUMERITY for patients intolerant to other DMFs.

---

What Are the Financial Trajectories for VUMERITY?

1. Revenue Growth Trends

Year	Estimated Revenue (USD Millions)	Notes
2019	\$50M	Initial launch
2020	\$150M	Accelerated uptake
2021	\$250M	Market expansion
2022	\$340M	Continued growth

Projection (2023–2027):

• Compound Annual Growth Rate (CAGR): ~25-30%, driven by increased market penetration and global expansion.

2. Market Penetration & Share Targets

• Targeted Market Share (2025): 10-15% of the oral DMT segment (~\$4-6 billion globally).
• Sales Forecasts:
  • US: \$500M by 2024
  • EU: \$200M additional by 2025
  • Emerging Markets: Rapid growth through licensing and partnerships

3. Factors Impacting Revenue

• Competition: Competing drugs like ozanimod and cladribine may constrain growth.
• Access & Reimbursement: Potential formulary restrictions could delay uptake.
• Pricing Strategies: Tiered pricing, copay assistance, and value-based agreements.

4. Profitability and Cost Dynamics

Component	Figures	Implications
R&D Expenses	Roughly 15% of revenue	Ongoing innovation
Marketing & Sales	20-25% of revenue	Focused on physician education
Gross Margin	~75%	Favorable, driven by high-margin specialty drugs
Net Margin	20-25%	Expected, depending on market access

5. Strategic Growth Initiatives

• Global Licensing and Partnerships: Expanding access in emerging markets.
• Line Extensions: Potential for combination therapies or novel formulations.
• Pipeline Synergies: Leveraging Biogen’s portfolio for synergistic growth.

---

How Does VUMERITY Compare with Its Competitors?

Attribute	VUMERITY	Tecfidera	Ocrevus	Mayzent	Ozanimod
Mechanism	Fumarate prodrug	Fumarate	Anti-CD20	S1P modulator	S1P modulator
Efficacy	Similar	Key efficacy	Higher efficacy	High efficacy	High efficacy
Side Effects	Reduced GI	Standard GI	Cardiovascular concerns	Less data	Similar to ozanimod
Market Share (2022)	7%	43%	15%	5%	10%
Dosage	BID	BID	IV	Once daily	Once daily

What Are the Key Market Risks and Opportunities?

Risks:

• Generic Competition: Patent cliff for Tecfidera could enable generics, reducing VUMERITY’s market share.
• Regulatory Setbacks: Delays or restrictions in key markets could hamper growth.
• Reimbursement Limitations: Payer pushback on high-priced MS drugs.

Opportunities:

• Expanding Patient Access in emerging markets.
• Growth in Transitioning Patients: From injectable to oral therapies.
• Innovative Formulations: Combination therapies and personalized medicine applications.

---

Conclusion: Projected Outlook for VUMERITY

VUMERITY stands poised for a robust growth trajectory driven by its superior tolerability profile, strategic global expansion, and an expanding relapsing MS population. While facing stiff competition from more established and emerging therapies, its differentiation and targeted marketing can sustain a CAGR of approximately 25-30% over the next five years. Strategic alliances, formulary wins, and continuous innovation will be critical to maintaining momentum.

---

Key Takeaways

• Market Position: VUMERITY holds a growing niche, focusing on improved GI tolerability, fostering adherence.
• Financial Outlook: Revenue is expected to reach \$500 million in the US alone by 2024, with global revenues surpassing \$1 billion by 2025.
• Competitive Edge: Differentiation through side-effect profile, but faces competition from newer agents with broader or higher efficacy.
• Market Risks: Patent expiration, reimbursement hurdles, and emerging biosimilars or generics.
• Growth Strategies: Focus on global expansion, pipeline development, and targeted physician education.

---

FAQs

Q1: How does VUMERITY's efficacy compare with Tecfidera?
A: Both drugs have similar efficacy profiles in reducing relapse rates, but VUMERITY offers a better GI tolerability profile, potentially improving adherence.

Q2: What is VUMERITY’s current market share in MS therapeutics?
A: As of 2022, VUMERITY’s share is approximately 7%, with room for growth as physicians shift towards more tolerable oral therapies.

Q3: What are the primary barriers to VUMERITY’s wider adoption?
A: Key barriers include physician familiarity with newer therapies, reimbursement policies, and patient acceptance.

Q4: What is the potential timeline for VUMERITY to become a market leader?
A: With continued growth, VUMERITY could capture 15% of the oral DMT market by 2025, but overtaking Tecfidera depends on market dynamics and pipeline developments.

Q5: Are there any notable pipeline or line extension plans for VUMERITY?
A: Currently, Biogen’s focus remains on maximizing its current indications; exploratory studies into combination treatments and formulations are under consideration but not yet launched.

---

References

[1] Biogen Inc. Official Product Monograph, 2019
[2] GlobalData, MS Drug Market Report, 2022
[3] FDA Approval Announcement, October 2019
[4] IQVIA MIDAS Database, 2022
[5] Market Analyst Reports, 2023